[Lu-177]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

Hofman, MS; Violet, J; Hicks, RJ; Ferdinandus, J; Thang, SP; Akhurst, T; Iravani, A; Kong, G; Kumar, AR; Murphy, DG; Eu, P; Jackson, P; Scalzo, M; Williams, SG; Sandhu, S

Hofman, MS (reprint author), Peter MacCallum Canc Ctr, Dept Canc Imaging, Melbourne, Vic 3000, Australia.

LANCET ONCOLOGY, 2018; 19 (6): 825

Abstract

Background Progressive metastatic castration-resistant prostate cancer is a highly lethal disorder and new effective therapeutic agents that improve p......

Full Text Link